Eiger BioPharmaceuticals: $45.2M Sale and Rare Equity Recovery
Eiger BioPharmaceuticals produced an outcome that is rare in chapter 11: a liquidation in which every class of creditors was paid in full and equity holders still received cash. The Palo Alto rare-disease drug developer sold its entire portfolio — anchored by the progeria treatment Zokinvy — through four court-supervised sales that generated roughly $87 million in gross proceeds, enough to satisfy secured and unsecured claims with interest and to return distributions to shareholders whose common stock was nonetheless cancelled. Eiger filed chapter 11 globenewswire.com: filed chapter 11 (outside source, not verified by ElevenFlo) on April 1, 2024 in the U.S. Bankruptcy Court for the Northern District of Texas (case no. 24-80040) before Judge Stacey G. C. Jernigan, listing about $38.8 million of assets and $53.1 million of liabilities mercurynews.com: about $38.8 million of assets and $53.1 million of liabilities (outside source, not verified by ElevenFlo).
The case was structured from day one as a sale process rather than a reorganization, but it did not end at confirmation. A protracted post-effective fight between the two principal asset buyers — Sentynl Therapeutics, which acquired Zokinvy, and Eiger InnoTherapeutics, which acquired the virology assets — over shared manufacturing infrastructure generated a roughly $45.2 million administrative expense claim and litigation that ran into 2026. The Fifth Amended Joint Plan of Liquidation was confirmed sidley.com: Fifth Amended Joint Plan of Liquidation was confirmed (outside source, not verified by ElevenFlo) on September 5, 2024 and became effective on September 30, 2024 investing.com: effective on September 30, 2024 (outside source, not verified by ElevenFlo).
| Debtor(s) | Eiger BioPharmaceuticals, Inc. (5 jointly administered entities) |
| Court | U.S. Bankruptcy Court, Northern District of Texas (Dallas Division) |
| Case Number | 24-80040 |
| Judge | Hon. Stacey G. C. Jernigan |
Table: Case Snapshot
Sale-Driven Liquidation and Case Path
Eiger entered chapter 11 to run a structured sale process for its drug portfolio while preserving patient access and funding operations through closing. The voluntary petition and First Day Declaration Dkt. 19 of David Apelian described the cases as a liquidation rather than a reorganization, and the debtors filed a Bidding Procedures Motion Dkt. 13 the same day. Cash was tight, and Innovatus Life Sciences Lending Fund I, LP held first-priority liens on substantially all assets, so the debtors needed cash collateral relief to operate. The court entered an interim cash collateral order on April 5, 2024 and a final cash collateral order on April 24, 2024, granting adequate protection through replacement liens and superpriority claims and imposing a budget with a 120% variance threshold for any rolling four-week period.
Asset sales then moved in rapid succession. The court approved the Zokinvy transaction on April 24, 2024 in a transfer free and clear of liens, approved the avexitide sale under a June 27, 2024 Avexitide Sale Order Dkt. 376, and entered a revised order on August 21, 2024 covering the remaining lonafarnib and peginterferon lambda assets. All four sales closed before or around plan confirmation, so by the time creditors voted, the estate had largely been converted to cash.
Rare-Disease Portfolio and Asset Value
Eiger was a commercial-stage biopharmaceutical company focused on rare diseases, headquartered in Palo Alto, California mercurynews.com: about $38.8 million of assets and $53.1 million of liabilities (outside source, not verified by ElevenFlo) with roughly nine full-time employees at the petition date. Its value to the estate was concentrated in a small number of orphan-drug programs, each carrying FDA Breakthrough Therapy designation, and in substantial tax attributes. The first day declaration reported approximately $322.5 million in federal net operating losses and $47.1 million in state NOLs as of December 31, 2023, along with research and orphan-drug tax credits — attributes significant enough that the court entered an NOL trading procedures order Dkt. 82 on April 5, 2024 to protect them.
The most commercially significant asset was Zokinvy (lonafarnib). Zokinvy received FDA approval in November 2020 prnewswire.com: FDA approval in November 2020 (outside source, not verified by ElevenFlo) as the first and only treatment for Hutchinson-Gilford progeria syndrome, with U.S. commercial availability in January 2021, and it later gained approvals in Europe, Great Britain, and Japan pharmaceutical-technology.com. Progeria affects about 400 children worldwide and carries an average life expectancy of about 14.5 years; Zokinvy was the only approved therapy and depended on a license from Merck that had to be transferred to any buyer. That dependence later became a contested issue when the estate rejected the Merck license.
Clinical Setbacks and Innovatus Defaults
Eiger's path to bankruptcy ran through a series of clinical and regulatory setbacks. In September 2022, the FDA rejected an emergency use authorization biospace.com: rejected an emergency use authorization (outside source, not verified by ElevenFlo) for peginterferon lambda as a COVID-19 treatment, removing a near-term regulatory path. In September 2023, the Phase III LIMT-2 trial of peginterferon lambda for chronic hepatitis delta was discontinued after safety concerns prnewswire.com: discontinued after safety concerns (outside source, not verified by ElevenFlo). The trial had enrolled 158 patients across 48 sites in 12 countries prnewswire.com: discontinued after safety concerns (outside source, not verified by ElevenFlo), and four patients experienced hepatobiliary events with liver decompensation; shares fell 36 percent in after-hours trading biospace.com: fell 36 percent in after-hours trading (outside source, not verified by ElevenFlo) on the news.
Innovatus Term Loan and Cash Collateral
Eiger's prepetition capital structure was anchored by a single Innovatus term loan facility. In June 2022 the company entered into a term loan agreement of up to $75 million prnewswire.com: term loan agreement of up to $75 million (outside source, not verified by ElevenFlo), with an initial draw of approximately $40 million and additional tranches of up to $35 million tied to regulatory and clinical milestones. The facility was secured by a first-priority interest in substantially all assets, including intellectual property, and the same transaction included a $5 million common stock purchase, making Innovatus both lender and equity investor. The loan and security agreement was dated June 1, 2022 and carried an August 31, 2027 maturity.
The first day declaration reported the facility's interest rate as the greater of Prime or 3.5 percent, plus 3.75 percent, producing an effective rate of 13.84 percent for the year ending December 31, 2023, with a portion of interest payable in kind in the early years. By the petition date the debtors reported $41,685,030.30 outstanding under the Term A loan. That balance fell sharply once the sales closed: the court later estimated the Innovatus claim Dkt. 561 at $15,738,961.47 solely for purposes of funding the Prepetition Term Loan Claims Escrow Account and rendering Innovatus unimpaired, reflecting substantial paydown from sale proceeds during the case.
The Final Cash Collateral Order Dkt. 161 authorized the debtors to use cash collateral subject to the budget and variance threshold, and provided Innovatus adequate protection through first-priority replacement liens on postpetition collateral and superpriority administrative claims, subject to a carve-out. Cash collateral funded operations and the marketing process while the debtors ran the four asset sales.
Innovatus was also active on the venue front. The U.S. Trustee filed an emergency motion in April 2024 arguing that Eiger — a Palo Alto company with nine employees — lacked sufficient ties to Texas to justify the Northern District filing. The bankruptcy court rejected that challenge on May 7, 2024 , ruling Eiger could remain in Dallas. Innovatus then appealed the venue ruling to the district court in late May, but the case proceeded to confirmation in Texas without a transfer. During plan solicitation, the court separately rejected Innovatus's bid for a $13 million attorney fee reserve within the plan, siding with the debtors on the scope of Innovatus's future claims.
Four Asset Sales and Auction Outcomes
The case proceeded as a multi-asset liquidation with four sale transactions, but only one drew a competitive auction. The Zokinvy sale was the anchor. Eiger entered chapter 11 with a stalking-horse agreement with Sentynl Therapeutics, and the auction reportedly ran through 35 rounds of bidding pharmaceutical-technology.com: Europe, Great Britain, and Japan (outside source, not verified by ElevenFlo) before Sentynl prevailed; Sentynl's announcement described a base price of $46.1 million sentynl.com: base price of $46.1 million (outside source, not verified by ElevenFlo), reduced by a $0.9 million termination fee credit to a net $45.2 million. The court approved the transfer of worldwide rights through the Zokinvy Sale Order Dkt. 162, and the sale closed on May 3, 2024 with Sentynl, a subsidiary of Zydus, as buyer. Eiger stated that patient access to Zokinvy would continue globenewswire.com: filed chapter 11 (outside source, not verified by ElevenFlo) without interruption during the process.
Avexitide produced the only true auction. Spruce Bioscience, Inc. served as stalking horse at $10 million, and competitive bidding more than tripled that figure: Amylyx Pharmaceuticals won the auction with a $35.1 million bid plus determined cure costs and assumed liabilities. The court entered the avexitide sale order on June 27, 2024, and Amylyx announced a July 9, 2024 closing, framing the acquisition as a pivot into the GLP-1 space with topline data targeted for 2026.
Liquidating Plan and Class 4 Upgrade
The Joint Plan of Liquidation Dkt. 424 established the framework for winding down Eiger and distributing the sale proceeds, organizing claims into six classes. The most consequential development for creditors came during solicitation. As initially solicited, Class 4 general unsecured claims were impaired with no distribution; the Fifth Amended Plan amended that treatment to provide post-petition interest through the distribution date, rendering Class 4 unimpaired and paid in full. The Confirmation Order Dkt. 639 approved an amended Disclosure Statement Dkt. 425 and confirmed the plan on September 5, 2024.
| Class | Description | Treatment | Recovery |
|---|
Confirmation Objections and Post-Effective Litigation
The plan drew two confirmation objections, both overruled, and several disputes that outlasted the effective date. U.S. Trustee objection. The U.S. Trustee objected Dkt. 587 on four grounds: that the plan's non-discharge injunction effectively functioned as an impermissible discharge for a liquidating debtor, that the exculpation provision exceeded Fifth Circuit authority, that the opt-out third-party releases were nonconsensual and unauthorized, and that the injunction enforcing the releases was overbroad. The Confirmation Order overruled all outstanding objections.
Equity Committee and D&O tail insurance. Because Eiger was publicly traded, the case produced both an Official Committee of Unsecured Creditors and an Official Equity Security Holders' Committee. The Equity Committee objected Dkt. 589 to the director-and-officer releases, arguing there was no justification for releases in a liquidation, that no consideration was being paid by the released parties, and that the debtors had spent $2.7 million in the two weeks before the petition to purchase approximately $20 million in D&O tail coverage — an asset the broad releases would have extinguished. The committee's own investigation of potential D&O claims was ongoing. The court overruled the objection and confirmed the plan with the releases.
Sentynl administrative claim and manufacturing disputes. The largest post-effective dispute was between the two buyers over shared manufacturing infrastructure. Sentynl filed a motion to enforce the Zokinvy Sale Order Dkt. 781 and for contempt, alleging that EIT Pharma blocked its access to Lonza Bend and Corden Pharma Colorado supply and data; EIT responded with its own emergency motion Dkt. 787 seeking confirmation that its lonafarnib purchase had transferred the Corden inventory and contracts. The parties entered an interim stipulation on May 2, 2025 giving Sentynl interim manufacturing access, and resolved all contested manufacturing matters by stipulation in July 2025. Separately, Sentynl filed a $45.2 million administrative expense claim — effectively the full Zokinvy purchase price — alleging post-petition breaches. The Liquidating Trustee objected that a December 2024 settlement with EIT had mooted the claim and moved for summary judgment, but the court denied summary judgment on May 28, 2025, allowing the contest to proceed. The administrative claim ultimately settled on undisclosed terms.
Professionals and Fee Awards
The debtors retained Sidley Austin as counsel, Alvarez & Marsal as financial advisor with Douglas Staut serving as CRO, and SSG Advisors as investment banker, as identified in the chapter 11 announcement globenewswire.com: filed chapter 11 (outside source, not verified by ElevenFlo), with Kurtzman Carson Consultants as claims and noticing agent. The two creditor committees added a second layer of professionals: Meland Budwick represented the UCC, while Porzio, Bromberg & Newman and McKool Smith served as co-counsel and Dundon Advisers as financial advisor to the Equity Committee. Final fee applications, all approved in October 2024, totaled roughly $14.4 million.
| Professional | Role | Fees approved |
|---|---|---|
| Sidley Austin LLP |
Liquidating Trust and Claims Reconciliation
The estate continued to wind down well into 2026 under a liquidating trust. Broadbent Advisors LLC initially served as Plan Administrator following the effective date, but resigned effective September 26, 2025 Dkt. 905, and Dundon Advisers LLC — already serving as Liquidating Trustee — was appointed successor, consolidating both roles. The trust's post-confirmation reports Dkt. 936 for the lead debtor showed approximately $13.56 million in total disbursements since the effective date as of the first quarter of 2026, including $5.75 million of an anticipated $6.74 million in equity distributions, $3.29 million of $3.76 million in general unsecured distributions, and $0.20 million of $0.28 million in priority distributions. No class distributions were made during the fourth quarter of 2025 or the first quarter of 2026; the quarter-over-quarter increase of roughly $278,000 reflected continued trust administrative spend.
Claims reconciliation extended the case timeline through successive deadline extensions. The Liquidating Trustee's Fourth Motion to Extend the claims objection deadline Dkt. 924 recorded that the Sentynl administrative claim, the Merck claims, and the Sciensus claim had all settled, and the court extended the bar date Dkt. 927 to July 20, 2026. The last meaningful contested thread was an avoidance and fraudulent-transfer track against claimant David Cory; rather than file an adversary complaint, the Trustee and Cory entered successive stipulations Dkt. 929 extending the filing deadline, and a further stipulation Dkt. 937 in May 2026 pushed it to June 24, 2026, citing a settlement agreement in principle subject to Oversight Committee approval.
Frequently Asked Questions
Why did Eiger BioPharmaceuticals file for chapter 11?
The immediate trigger was a default declared by secured lender Innovatus under the company's term loan, and the resulting threat of enforcement. That followed a string of clinical setbacks, including the FDA's rejection of an emergency use authorization biospace.com: rejected an emergency use authorization (outside source, not verified by ElevenFlo) for peginterferon lambda in 2022 and the discontinuation of the Phase III LIMT-2 study prnewswire.com: discontinued after safety concerns (outside source, not verified by ElevenFlo) in 2023, with liabilities exceeding assets at filing.
Who bought Zokinvy and for how much?
Sentynl Therapeutics, a subsidiary of Zydus, acquired Zokinvy after an auction that produced a base price of $46.1 million sentynl.com: base price of $46.1 million (outside source, not verified by ElevenFlo) and a $0.9 million termination fee credit, for a net $45.2 million. The sale closed on May 3, 2024.
What happened to the other drug assets?
Amylyx Pharmaceuticals acquired avexitide for $35.1 million after outbidding stalking horse Spruce Bioscience, and Eiger InnoTherapeutics (now EIT Pharma) bought the lonafarnib hepatitis delta program for $5.2 million and the peginterferon lambda assets for $1.0 million, both as the sole qualified bidder.
Sources
- Dkt. 13Debtors’ Motion for Entry of an Order (I)(A) Approving the Bid Procedures; (B) Authorizing the Debtors to Select Sentynl Therapeutics, Inc. as the Zokinvy Stalking Horse Purchaser & Approving Bid Protections; (C) Approving the Bid Protections Relating to the Remaining Assets Stalking Horse Purchaser(s), If Any; (D) Establishing Bid Deadlines, Auction(s), and Sale Hearing(s); (E) Approving the Form and Manner of Sale Notice; (F) Approving Assignment and Assumption Procedures; (G) Approving the Form and Manner of Potential Assumption and Assignment Notice; (II)(A) Authorizing the Sale of the Assets Free and Clear; and (B) Approving the Assumption and Assignment of Designated Contracts; and (III) Granting Related Relief (Filed by Debtor Eiger BioPharmaceuticals, Inc.)Filed Apr 1, 2024Apr 1, 2024
- Dkt. 19First Day DeclarationFiled Apr 1, 2024Apr 1, 2024